A high level of CEA can be a sign of certain types of cancers. These include cancers of the colon and rectum, prostate, ovary, lung, thyroid, or liver. High CEA levels may also be a sign of some noncancerous conditions, such as cirrhosis, noncancerous breast disease, and emphysema.
CEA is a protein polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain malignancies to therapy. CEA may be medically necessary for follow-up of patients with colorectal carcinoma.
R97. 8 - Other abnormal tumor markers. ICD-10-CM.
The CEA blood level may be increased in non-cancerous conditions including:a peptic ulcer.ulcerative colitis.rectal polyps.emphysema.benign breast disease.an inflammation such as pancreatitis (inflammation of the pancreas) or cholecystitis (inflammation of the gallbladder)
To summarize, NCD 190.26 provides, under the heading “Indications,” that a CEA test “may be medically necessary,” and thus covered by Medicare, for two broad groups of patients: (1) patients with colorectal cancer; and (2) patients with other types of cancer when the cancer tumor does not express a “more specific ...
Doctors don't use the CEA test to make a first-time diagnosis of cancer. This test isn't an accurate way to screen for it because many other diseases can cause the levels of this protein to rise. And some people with cancer don't have high CEA levels.
LOINC MapOrder CodeOrder Code NameResult Code002253AFP, Serum, Tumor Marker002266
NCD - Tumor Antigen by Immunoassay - CA 19-9 (190.30) The .
CA 19-9 is a type of tumor marker. Tumor markers are substances made by cancer cells or by normal cells in response to cancer in the body. Healthy people can have small amounts of CA 19-9 in their blood. High levels of CA 19-9 are often a sign of pancreatic cancer.
Oxaliplatin has been shown to cause an inflammatory response which appears to be one of the mechanisms of toxicity and high CEA levels have been correlated with increased inflammation.
For patients with colonic adenocarcinoma receiving adjuvant chemotherapy, any rise in CEA level should prompt thorough evaluation for disease recurrence; however, in the absence of disease, it should be noted that inflammatory changes could be the trigger of a CEA rise.
SARS-CoV-2 infection might be another cause of CEA elevation, with nearly 20% of patients experienced transient and marked CEA increment during COVID-19 pneumonia. The false-positive results of CEA elevation might have clinical significance for patients with colorectal cancer.